BioSpace News Archive

PDL BioPharma, Inc. announced upcoming changes to the Company’s Board of Directors.

Awards of $10 Million in 2019 Granted to More Than 400 Organizations in 32 States

BrainStorm Cell Therapeutics, Inc. announced that the clinical trial independent Data Safety Monitoring Board has completed the first, pre-specified interim analysis, of safety outcomes for 9 participants enrolled in the Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

Brains Bioceutical Corp. (“Brains”) is pleased to announce the completion of its US$30m Capital Raise, including US$19m raised exclusively by Canaccord Genuity, and strategic partnership with a leading European Medical Cannabis Group.

In an open letter published today in several top U.S. newspapers, Eli Lilly and Company (NYSE: LLY) Chairman and CEO Dave Ricks encouraged anyone who needs help affording their monthly prescription of Lilly insulin to call the Lilly Diabetes Solution Center where they can find cost-saving options that meet their personal circumstances.

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced that board member S. Louise Phanstiel has been named to WomenInc. Magazine’s 2019 Most Influential Corporate Board Directors list.

Axsome Therapeutics, Inc. (Nasdaq: AXSM) (“Axsome” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $87.00 per share.

Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) announces 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its diastolic pressure algorithm (“dPR”).

Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of innovative cell therapies to treat cancer, today announced plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine